Allianz Research Institute

Westminster, California 92683

0 studies enrolling now · 10 studies all time

What they study most

Asthma, COVID-19, Cardiovascular Disease, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension, Severe Asthma

Studies at this site

• A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD — Running, not enrolling
• Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma — Running, not enrolling
• A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) — Running, not enrolling
• A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT) — Completed
• Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma — Stopped early
• A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma — Completed
• A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness — Completed
• A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension — Stopped early
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early